Fusion Antibodies are specialists in pre–clinical antibody discovery, engineering and supply for both therapeutic drug and diagnostic applications.
Established in 2001 as a spin–out from Queen’s University Belfast, Fusion Antibodies mission is to enable drug discovery companies to develop innovative products in a timely and cost–effective manner for the benefit of the global healthcare industry.
The company has an international, blue–chip client base which includes 8 of the top 10 global pharmaceutical companies by revenue.
Fusion Antibodies plc can be separated into 3 sectors; antibody discovery, engineering and supply. The company’s experience and expertise in generating antibodies has shown the value of drawing from a repertoire of antigen design options, immunisation scheduling, host species, screening strategies as well as their 17 years expertise. Due to the company’s expertise it has been appointed by the US court of Delaware as expert witnesses in multibillion–dollar drug cases involving top 10 ranked pharmaceutical companies.
Fusion Antibodies offer a range of antibody engineering services including;
- Cell Line Development
- Antibody Developability
- Affinity Maturation
Beyond this, the company offer gene to protein expression, antibody characterisation and cell line development, all of which they work extremely closely with their clients to provide a tailored service.
- International client base including a number of top 10 Pharma companies